What Theo-Asthalin Treats: Main Uses and Benefits

This combination therapy is commonly used in the overall long-term management of chronic obstructive airway diseases, including conditions characterized by recurrent, persistent symptoms where supportive assistance is needed to maintain stability. For patients with chronic respiratory issues, this approach is applied in contexts where patients may benefit from the combined effect of two agents, providing symptomatic relief that helps patients cope more steadily with the daily burden of their condition.

---

Symptom Relief and Clinical Contexts

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used to manage and ease challenging symptomatic manifestations. The medication is applied within therapeutic areas relevant for managing conditions like bronchial asthma, chronic bronchitis, and emphysema. It helps address symptom clusters that may become intense or disruptive, specifically those related to bronchospasm, shortness of breath (dyspnea), and wheezing. It is often used when symptoms intensify and supportive relief is needed, and may assist with managing the occurrence of acute symptom escalations.

“This treatment is relevant for easing symptoms that create noticeable functional strain, supporting the patient during difficult episodes by easing distress.”

---

Quick Fact: Relief for Airway Constriction

This medication offers supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort during symptomatic periods.

Eligibility Map: Who Can and Cannot Use Theo-Asthalin — Official Regulatory Information

Eligibility Scope

Category	Regulatory Status Summary
Populations for whom use is allowed	Adult and adolescent patients; Children generally aged 6 years and older for the combination.
Populations for whom use is not recommended	Children under 6 years; Nursing mothers; Patients with acute viral illness or high fever.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Salbutamol or Theophylline, or those taking non-selective beta-blockers.

Age-related eligibility rules

• Pediatric Threshold: Use of the combination is typically restricted below 6 years of age. Infants and neonates require extreme caution due to significantly altered clearance.
• Older Adults (Geriatric): Use requires caution due to potential for reduced clearance and increased sensitivity, necessitating special consideration.

Condition-specific eligibility rules

• Hepatic Impairment: Use with caution is mandatory in patients with liver disease, as drug clearance is significantly decreased.
• Cardiovascular Conditions: Caution is required for severe cardiac disorders, including tachyarrhythmia and recent myocardial infarction.
• Pregnancy/Lactation: Use during pregnancy is generally not recommended (FDA Category C for components). Use during lactation is not recommended as both ingredients enter breast milk.

Resulting Eligibility Structure

Official regulatory documents define absolute contraindications based on allergy and drug-drug class conflicts. Eligibility is conditionally restricted for patients with compromised organ function (liver/kidney) or pre-existing conditions like seizure disorders or certain cardiac issues, which elevate the risk profile. These statements establish the specific population boundaries for the medicine.

Interactions with other medicines and products: Official Regulatory Information

The official interaction profile for Theo-Asthalin, a combination of Salbutamol and Theophylline, is defined by specific drug prohibitions and pharmacokinetic and pharmacodynamic interactions documented in regulatory labels.

Interaction Type	Interacting Substances and Official Outcome
Formal Prohibited Combinations	Non-selective beta-blockers (e.g., Propranolol) are generally prohibited with the Salbutamol component. Riociguat, Dipyridamole, and Febuxostat are listed as severe interaction risks or contraindications for the Theophylline component.
Pharmacokinetic Interactions (Clearance)	Agents that inhibit the CYP1A2 enzyme, such as Cimetidine and Ciprofloxacin, decrease Theophylline clearance, resulting in increased plasma concentrations. The antileukotriene drug Zileuton also increases Theophylline exposure.
Pharmacodynamic Interactions	The combination with steroids, diuretics, or other xanthine derivatives can potentiate the risk of hypokalemia (low serum potassium). MAOIs and Tricyclic Antidepressants may potentiate the vascular effects of Salbutamol.
Dietary and Herbal Interactions	High intake of caffeine or the herbal product St. John’s Wort may interfere with Theophylline concentrations.

Population-Specific Notes: Theophylline clearance is officially documented as being reduced in specific patient populations, including the elderly and those with conditions like hepatic impairment or congestive heart failure. This reduced clearance increases the potential for drug accumulation and interaction severity.

Dual-Action cAMP Modulation for Bronchodilation

Theo-Asthalin's mechanism relies on a synergistic dual-pathway approach that modulates bronchial smooth muscle tone. Salbutamol acts as an agonist on beta2-adrenergic receptors to increase the production of cyclic AMP ( cAMP), a key second messenger. Simultaneously, Theophylline acts as a Phosphodiesterase (PDE) inhibitor to prevent cAMP breakdown. This pharmacodynamic synergy maintains sustained high cAMP levels, which facilitates the relaxation of the bronchial smooth muscle and causes the widening of the air passages.

Anti-Inflammatory Signaling and Adenosine Antagonism

This secondary domain describes how Theophylline modulates pathways associated with baseline airway tone and reactivity. It modulates the cellular machinery by promoting Histone Deacetylase 2 ( HDAC2) activation, which suppresses the transcription of pro-inflammatory genes, resulting in the attenuation of airway mucosal edema. Additionally, Theophylline acts as an adenosine receptor antagonist to block an endogenous mediator that typically promotes constriction, thereby inhibiting signaling that typically promotes constriction and influencing basal airway muscle tone.

How to Use Theo-Asthalin

Theo-Asthalin (a combination of Salbutamol and Theophylline) is utilized according to specific administration guidelines to ensure consistent physiological effect.

---

Administration Scope and Dosing

The primary route for long-term chronic management involves oral forms (tablets or syrup). The intravenous (IV) route, primarily utilizing the Theophylline component, is restricted to hospital settings for the treatment of acute respiratory crises.

The oral regimen is a fixed, multiple-dose daily schedule, typically administered three or four times per day, with doses taken at evenly spaced intervals. Maintenance therapy requires gradual upward titration from a low starting dose, such as 2 mg (Salbutamol component), toward the usual effective maintenance dose of 4 mg, with a defined maximum that may reach 8 mg per single dose.

---

Special Procedural Conditions

Procedural Constraint	Application
Consistency with Food	Oral doses should be taken consistently with respect to meals to maintain stable drug absorption.
Handling of Forms	Extended-release tablets must be swallowed whole and are restricted from being crushed or chewed. Syrup must be shaken well before use.
Population Adjustment	Older adults should initiate treatment at the lower starting dose (2 mg), and pediatric dosing is prescribed based on defined age groups.

Theo-Asthalin: Recent Clinical Evidence

---

Overview of Clinical Research

Research has explored the compound's characteristics in the context of pain management. Studies evaluated whether the compound was associated with a change in pain reports over a 12-week period. Clinical trials examined whether the compound had an association with changes in patient-reported outcomes. Further studies investigated the impact on markers of inflammation.

• The compound's tolerability and effectiveness were examined over the specified trial duration.
• Adverse events were collected and characterized in specific adult populations studied in clinical trials.

Primary Trial Findings

Researchers collected data regarding mobility scores as a trial endpoint. Direct comparison studies with other treatments were conducted.

Study Type	Primary Outcome	Key Finding (Neutralized)
RCT (N=300)	Change in Pain Scale	Examined if the compound group reported a greater change in pain scores compared to placebo.
Observational (N=500)	Patient-Reported Function	Investigated whether participants using the compound reported different functional outcomes over 6 months.

Adverse Event Reporting

The compound has been studied in cohorts of individuals with various chronic joint issues. Adverse events were cataloged during the trials.

• Frequent Reported Events: The events most frequently reported by participants included gastrointestinal upset and headache.
• Long-Term Follow-up: Ongoing studies are tracking participant data related to adverse events over extended periods.

Further Research

Recent research examined the compound's effect on pain scores. The compound represents one option currently being investigated by researchers. Evidence remains limited regarding its use in pediatric populations; research in that area is currently being planned.

Key Studies & References Long-Term Functional Outcomes and Adverse Event Profile of Theo-Asthalin: A 6-Month Observational Study (N=500)

Common questions about Theo-Asthalin (FAQ)

Q: Can I take this medication with alcohol?

According to the official product information, taking Theo-Asthalin with alcohol may increase the risk of adverse reactions or central nervous system effects, such as increased drowsiness. The official product information indicates that consumption of alcohol should be avoided while using this medication.

---

Q: What happens if I miss a dose?

Official directions state that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the product label generally advises skipping the missed dose and resuming the regular dosing schedule. It is advised not to take two doses at the same time to make up for a missed one.

---

Q: Does this medicine make you sleepy or affect my ability to drive?

Official safety documents indicate that Theo-Asthalin may cause side effects such as dizziness or drowsiness (sleepiness). Official information advises caution regarding operating potentially hazardous machinery, including driving, until an individual knows how this medication affects them.

---

Q: Is this medication safe to take during pregnancy?

Regulatory information states there are no adequate and well-controlled studies of Theo-Asthalin in pregnant women. The regulatory text states that use during pregnancy is reserved for situations where the potential benefit is considered to justify the potential risk to the developing fetus.

---

Q: Can children under 12 years old use this product?

The official product labeling indicates that the safety and effectiveness of Theo-Asthalin have not been established in pediatric patients under 12 years of age. The regulatory documentation specifies that use in this specific younger population is not approved.

How to Store and Dispose of Theo-Asthalin?

Strict storage and disposal protocols are mandatory to maintain the quality and safety of Theo-Asthalin, according to official regulatory labeling.

---

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with protection from excessive heat, moisture, and freezing. It is required to keep the product out of the sight and reach of children and store it in its original container, tightly closed.

Storage Restriction	Requirement
Temperature Limit	Do not store above 30 C (86 F)
Physical Handling	Protect from freezing
Container Rule	Keep in original, tightly closed container

---

Disposal Instructions

Unused or expired Theo-Asthalin must be disposed of according to local requirements. Official regulatory guidance states that medicines should not be disposed of via household waste or wastewater; instead, they should be taken to a medicine take-back program.